Skip to content

Midline Versus Dorsolateral Spinal Cord Stimulation for Post-surgical Neuropathic Pain

Midline Versus Dorsolateral Spinal Cord Stimulation for Post-surgical Neuropathic Pain (MIDL-SCS Trial)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06390150
Acronym
MIDL-SCS
Enrollment
40
Registered
2024-04-30
Start date
2025-09-30
Completion date
2030-07-31
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic Pain, Pain, Postoperative

Keywords

Spinal cord stimulation, Post intra-thoracic surgery pain syndrome

Brief summary

The goal of this interventional study is to learn if dorsolateral spinal cord stimulation (DL-SCS) can treat focal post-surgical, medically refractory neuropathic pain. The main question it aims to answer is: \- How does DL-SCS compare to traditional SCS and no treatment for treating post-surgical neuropathic pain? Participants will be asked to * trial combinations of stimulation across blocks of weeks (randomized cross-over) * rate their pain after each stimulation trial

Detailed description

Neuropathic pain resulting from injury to the somatosensory nervous system can be a persistent and debilitating condition of spontaneous and unprovoked symptoms. For patients with chronic neuropathic pain that does not respond to conservative therapy, spinal cord stimulation (SCS) may be considered. SCS has been established as an effective and sustained treatment for neuropathic pain, but may deliver treatment to more than just the pain area. Dorsolateral spinal cord stimulation (DL-SCS) may provide a more focal alternate target for spinal stimulation. The aim of this study is to investigate DL-SCS as a therapeutic option for post-surgical, medically refractory neuropathic pain. This is a prospective, randomized, double-blind controlled crossover trial to investigate the efficacy of DL-SCS and midline SCS (M-SCS) compared to sham stimulation for the diagnosis of post-surgical neuropathic pain. Each participant will be implanted with two electrodes and will crossover into each stimulation program in a randomized order to serve as their own control.

Interventions

DEVICESpinal Cord Stimulator

The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.

Sponsors

Nova Scotia Health Authority
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

This study will be conducted as a placebo-controlled, crossover, randomized clinical trial of the intervention dorsolateral spinal cord stimulation (DL-SCS) for the indication post-surgical focal neuropathic pain. Study arm order will be randomly generated and known only to the programmer. Once participants have crossed over into all study arms, they will be set on their best program and enter long-term observation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of neuropathic pain following a surgical procedure 2. A minimum of 50% of pain should be limited to one body part, defined as one limb or one side of trunk. 3. Failed conservative therapies (medication, physiotherapy) 4. Disability more than 6 months

Exclusion criteria

1. Previous implantation with SCS (i.e. revision surgery) 2. Any underlying condition that would preclude an MRI 3. Untreated psychiatric conditions or substance use disorder 4. Existing medical conditions that would preclude from SCS (history of recurrent infections, uncontrolled cancer, etc.) 5. Surgically treatable lesion (e.g. spinal stenosis, disc herniation) 6. Lack of capacity (e.g. significant cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline on the Numerical Rating Scale (NRS) for pain intensityBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryThe primary outcome is the self-reported difference in change from baseline of the severity of pain quantified in the Numerical Rating Scale. This will be assessed at baseline (pre-surgery) and at regular follow-up appointments.

Secondary

MeasureTime frameDescription
Change in score on Oswestry Disability IndexBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryAssesses a patient's quality of life in relation to back pain on a 10-section questionnaire. A low score indicates no disability and a high score indicates severe disability.
Change in score on EuroQol 5 Dimension QuestionnaireBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryAssesses overall quality of life in five dimensions including mobility, self-care, daily routine, pain, and anxiety/depression. A low score indicates poor health and a high score indicates excellent health.
Change in morphine equivalents usedBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryMeasures patient pain by assessing the amount of pain medication taken by a patient. Higher usage indicates a greater level of pain and a lower usage indicates a lower level of pain.
Change in score on the Brief Pain Inventory Short FormBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryAssesses the impact of pain on a patient's quality of life. A high score indicates a severe impact and a lower score indicates minimal impact.
Change in score on the 12-item Short Form SurveyBaseline and at 4, 6, 8, 10, 52, 104 weeks post-surgeryAssesses how a patient's health impacts their quality of life. A higher score indicates a better quality of life, and a low score indicates a poorer quality of life.

Countries

Canada

Contacts

Primary ContactLutz Weise, MD, PhD
ally.klassen@nshealth.ca902-472-6850

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026